Related Experiment Videos
Sequence databases and microarrays as tools for identifying prostate cancer biomarkers.
L H Grouse1, P J Munson, P S Nelson
1Office of Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Urology
|April 11, 2001
Summary
Identifying molecular markers is crucial for evaluating prostate cancer treatments. Advances in genomics and biotechnology enable the analysis of gene expression patterns as potential signatures for treatment response.
Area of Science:
- Genomics
- Biotechnology
- Prostate Cancer Research
Background:
- Molecular markers are needed as surrogate endpoints for prostate cancer interventions.
- Genomics and biotechnology have advanced the study of prostate carcinogenesis.
- Comprehensive databases and gene expression data are now more accessible.
Purpose of the Study:
- To identify and assess molecular markers for evaluating prostate cancer intervention responses.
- To leverage advances in genomics and biotechnology for prostate cancer research.
Main Methods:
- Utilizing comprehensive databases for virtual queries to distinguish normal and cancer cells.
- Employing robotic tools to construct microarrays for simultaneous gene expression monitoring.
- Assessing gene expression patterns as potential signatures of therapeutic response.
Main Results:
- Gene expression data is now suitable for virtual queries.
- Microarrays allow simultaneous monitoring of thousands of genes.
- Gene expression 'fingerprints' can serve as signatures for therapeutic intervention.
Conclusions:
- Advances in genomics and biotechnology facilitate the identification of molecular markers for prostate cancer.
- Gene expression profiling using microarrays shows promise for assessing treatment response signatures.